Compare Etsy Inc (ETSY) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Etsy Inc vs Mesoblast Limited — how do they compare? Etsy Inc trades at $76.71 (market cap $6.90B), while Mesoblast Limited trades at $14.29 (market cap $1.75B). The key difference: Etsy Inc is far larger — about 3.9× Mesoblast Limited's market cap, and Etsy Inc is trading nearer its 52-week high, Mesoblast Limited nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Etsy Inc for 67 Days and Mesoblast Limited for 15 Days on average.
| ETSY | MESO | |
|---|---|---|
Market Cap | $6.90B | $1.75B |
Volume | 2,923,867 | 239,027 |
Sector | Consumer Cyclical | Health |
52-Week High | $87.03 | $20.96 |
52-Week Low | $44.05 | $13.19 |
Typical Hold Time | 67 Days | 15 Days |
Enterprise Value | $8.85B | $1.83B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ETSY trades at $75.14, up 5.11% today, showing strong momentum with three consecutive earnings beats. The stock maintains a bullish technical outlook with support at $73 and resistance at $76. Fundamentally, revenue growth has been steady at $2.9B annually, though net margins compressed to 5.65% in 2025. Recent news highlights AI integration and payment partnerships as growth catalysts.
The outlook remains positive with a $85.94 analyst price target suggesting 14% upside. Key risks include high debt levels and competitive pressures. Wall Street sentiment is bullish (53% buy ratings), but investors should monitor margin trends and execution of AI initiatives for sustained growth.
MESO trades at $14.29, up 2.51% today, amid bearish technical signals but positive fundamental developments. The stock shows strong revenue growth with FY2026 reaching $120 million, though profitability remains negative. Recent FDA approval for Ryoncil's potency assay and completion of Phase 3 back pain trials provide catalysts. Technical indicators show oversold conditions with RSI at 22.4, while moving averages signal bearish momentum.
Investment outlook balances high growth potential against persistent losses. The expanding Ryoncil market share and pipeline progress offer upside, but negative margins and cash burn pose risks. Analyst consensus leans bullish with 45% buy ratings, yet the stock faces execution challenges in achieving profitability amid competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Etsy Inc
Etsy operates a top-10 e-commerce marketplace operator in the U.S. and the U.K., with sizable operations in Germany, France, Australia, and Canada. The firm dominates an interesting niche, connecting buyers and sellers through its online market to exchange vintage and craft goods. With $13.5 billion in 2021 consolidated gross merchandise volume, the firm has cemented itself as one of the largest players in a quickly growing space, generating revenue from listing fees, commissions on sold items, advertising services, payment processing, and shipping labels. As of the end of 2021, the firm connected more than 96 million buyers and more than 7.5 million sellers on its marketplace properties: Etsy, Reverb (musical equipment), Elo7 (crafts in Brazil), and Depop (clothing resale).
Read more on ETSY →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
